NEK2 Serves as a Novel Biomarker and Enhances the Tumorigenicity of Clear-CellRenal-Cell Carcinoma by Activating WNT/β-Catenin Pathway.

Zhou J, Lai J, Cheng Y, Qu W

Open source

DOI
10.1155/2022/1890823
Published
2022
Container
Evidence-based complementary and alternative medicine : eCAM
Publisher
Not recorded
Open access
yes

Credibility signals

serious concern Score 10/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1155/2022/1890823,
  title = {NEK2 Serves as a Novel Biomarker and Enhances the Tumorigenicity of Clear-CellRenal-Cell Carcinoma by Activating WNT/β-Catenin Pathway.},
  author = {Zhou J and Lai J and Cheng Y and Qu W},
  year = {2022},
  journal = {Evidence-based complementary and alternative medicine : eCAM},
  doi = {10.1155/2022/1890823},
  url = {https://doi.org/10.1155/2022/1890823}
}

RIS

TY  - JOUR
TI  - NEK2 Serves as a Novel Biomarker and Enhances the Tumorigenicity of Clear-CellRenal-Cell Carcinoma by Activating WNT/β-Catenin Pathway.
AU  - Zhou J
AU  - Lai J
AU  - Cheng Y
AU  - Qu W
PY  - 2022
JO  - Evidence-based complementary and alternative medicine : eCAM
DO  - 10.1155/2022/1890823
UR  - https://doi.org/10.1155/2022/1890823
ER  - 

APA

J, Z., J, L., Y, C., & W, Q. (2022). NEK2 Serves as a Novel Biomarker and Enhances the Tumorigenicity of Clear-CellRenal-Cell Carcinoma by Activating WNT/β-Catenin Pathway.. Evidence-based complementary and alternative medicine : eCAM. https://doi.org/10.1155/2022/1890823

Source records